Blood Cancer News and Research

RSS

Exposure to smoking and mutations in blood cells may lead to a rare cancer that affects immune cells

Mutations in blood cells likely caused by smoking and aging-related changes may lead to a rare type of blood cancer that affects immune cells, shows a study published today in eLife.

28 Sep 2021

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness.

27 Sep 2021

Covid-overwhelmed hospitals postpone cancer care and other treatment

It's a bad time to get sick in Oregon. That's the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated.

17 Sep 2021

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer.

12 Sep 2021

Distinct changes found in cancer and non-cancer immune cells in Waldenstrom macroglobulinemia

A new study by researchers at Winship Cancer Institute of Emory University finds that cancer-associated mutations originate in blood progenitor cells, leading to distinct changes in both cancer and non-cancer immune cells in Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma and its precursor IgM monoclonal gammopathy of undetermined significance (MGUS).

2 Sep 2021

CRISPR screening tool pinpoints new therapeutic target to treat acute myeloid leukemia

A CRISPR screening tool identified a new therapeutic target to treat acute myeloid leukemia (AML) that has the potential to leave patients with fewer side effects than current approaches, according to a new study from Penn Medicine published online in Molecular Cell.

18 Aug 2021

UC San Diego scientists develop new method to keep cultured cells healthy

Hematopoietic stem cells — the precursors to blood cells — have been notoriously difficult to grow in a dish, a critical tool in basic research.

12 Aug 2021

New study offers insight into how high-risk form of blood cancer can develop in children

In some children with acute myeloid leukemia, cancer cells have the same amount of DNA changes as healthy blood stem cells.

6 Aug 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

21 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Two CU Cancer Center studies provide insights into the link between inflammation and leukemia

Two recent collaborative publications by CU Cancer Center members provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers.

29 Jun 2021

Study maps potential link between oil and gas production and childhood leukemia risk

A pilot study of childhood leukemia patients living near Colorado's oil and gas drilling sites recently led to an American Cancer Society grant award for CU Cancer Center member Lisa McKenzie PhD, MPH.

28 Jun 2021

Blood cancer patients show widely variable response to COVID-19 vaccines

Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines--in some cases, no detectable response--pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study that will be published in Cancer Cell this week.

28 Jun 2021

Researchers uncover new function of regulator protein in multiple myeloma development

A specific regulatory protein significantly influences the development of tumor-inducing blood vessels in the bone marrow of blood cancer patients.

24 Jun 2021

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three members of the University of Colorado Cancer Center and a longstanding supporter of the campus are part of a group of more than 200 researchers nationwide who were recognized in April with the Team Science Award from the American Association for Cancer Research.

23 Jun 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

From Rapid Novor Inc 21 Jun 2021

Convalescent plasma associated with better survival in blood cancer patients with COVID-19

Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. The findings by the COVID-19 and Cancer Consortium (CCC19) are newly published in the peer-reviewed journal JAMA Oncology.

18 Jun 2021

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus.